Skip to main content
Top

Open Access 04-05-2024 | Obesity | REVIEW

A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle

Authors: Alba Rodriguez-Muñoz, Hanieh Motahari-Rad, Laura Martin-Chaves, Javier Benitez-Porres, Jorge Rodriguez-Capitan, Andrés Gonzalez-Jimenez, Maria Insenser, Francisco J. Tinahones, Mora Murri

Published in: Current Obesity Reports

Login to get access

Abstract

Purpose of Review

The present study aims to review the existing literature to identify pathophysiological proteins in obesity by conducting a systematic review of proteomics studies. Proteomics may reveal the mechanisms of obesity development and clarify the links between obesity and related diseases, improving our comprehension of obesity and its clinical implications.

Recent Findings

Most of the molecular events implicated in obesity development remain incomplete. Proteomics stands as a powerful tool for elucidating the intricate interactions among proteins in the context of obesity. This methodology has the potential to identify proteins involved in pathological processes and to evaluate changes in protein abundance during obesity development, contributing to the identification of early disease predisposition, monitoring the effectiveness of interventions and improving disease management overall. Despite many non-targeted proteomic studies exploring obesity, a comprehensive and up-to-date systematic review of the molecular events implicated in obesity development is lacking. The lack of such a review presents a significant challenge for researchers trying to interpret the existing literature.

Summary

This systematic review was conducted following the PRISMA guidelines and included sixteen human proteomic studies, each of which delineated proteins exhibiting significant alterations in obesity. A total of 41 proteins were reported to be altered in obesity by at least two or more studies. These proteins were involved in metabolic pathways, oxidative stress responses, inflammatory processes, protein folding, coagulation, as well as structure/cytoskeleton. Many of the identified proteomic biomarkers of obesity have also been reported to be dysregulated in obesity-related disease. Among them, seven proteins, which belong to metabolic pathways (aldehyde dehydrogenase and apolipoprotein A1), the chaperone family (albumin, heat shock protein beta 1, protein disulfide-isomerase A3) and oxidative stress and inflammation proteins (catalase and complement C3), could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, contributing to personalized medicine in the field of obesity. Our systematic review in proteomics represents a substantial step forward in unravelling the complexities of protein alterations associated with obesity. It provides valuable insights into the pathophysiological mechanisms underlying obesity, thereby opening avenues for the discovery of potential biomarkers and the development of personalized medicine in obesity
Appendix
Available only for authorised users
Literature
18.
go back to reference Jelski W, Sani TA, Szmitkowski M. Class III alcohol dehydrogenase and its role in the human body. Postepy Hig Med Dosw (Online). 2006;60:406–9.PubMed Jelski W, Sani TA, Szmitkowski M. Class III alcohol dehydrogenase and its role in the human body. Postepy Hig Med Dosw (Online). 2006;60:406–9.PubMed
101.
go back to reference Gibieža P, Petrikaitė V. The regulation of actin dynamics during cell division and malignancy. Am J Cancer Res. 2021;11(9):4050–69.PubMedPubMedCentral Gibieža P, Petrikaitė V. The regulation of actin dynamics during cell division and malignancy. Am J Cancer Res. 2021;11(9):4050–69.PubMedPubMedCentral
136.
165.
go back to reference Zhang Y, Wang L, Zheng X, Wang H, Wang G. Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Pak J Pharm Sci. 2023;36(4)(Special):1297–1303. Zhang Y, Wang L, Zheng X, Wang H, Wang G. Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Pak J Pharm Sci. 2023;36(4)(Special):1297–1303.
170.
go back to reference Zilaee M, Kermany T, Tavalaee S, Salehi M, Ghayour-Mobarhan M, Ferns GAA. Barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity c-reactive protein in patients with metabolic syndrome: a double-blind, randomized placebo-controlled trial. Phytother Res. 2014;28(8):1211–5. https://doi.org/10.1002/ptr.5117.CrossRefPubMed Zilaee M, Kermany T, Tavalaee S, Salehi M, Ghayour-Mobarhan M, Ferns GAA. Barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity c-reactive protein in patients with metabolic syndrome: a double-blind, randomized placebo-controlled trial. Phytother Res. 2014;28(8):1211–5. https://​doi.​org/​10.​1002/​ptr.​5117.CrossRefPubMed
Metadata
Title
A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle
Authors
Alba Rodriguez-Muñoz
Hanieh Motahari-Rad
Laura Martin-Chaves
Javier Benitez-Porres
Jorge Rodriguez-Capitan
Andrés Gonzalez-Jimenez
Maria Insenser
Francisco J. Tinahones
Mora Murri
Publication date
04-05-2024
Publisher
Springer US
Keywords
Obesity
Obesity
Published in
Current Obesity Reports
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-024-00561-4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare